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transition (EMT). We found that miR-134 expression correlated with invasive potential and EMT
phenotype of NSCLC cells. Functional assays demonstrated that miR-134 inhibited EMT in NSCLC
cells. In addition, we showed that Forkhead Box M1 (FOXM1) is a direct target of miR-134. Knock-
down of FOXM1 reversed EMT resembling that of miR-134 overexpression. We further found that
FOXM1 was involved in TGF-b1-induced EMT in A549 cells. These ﬁndings suggest that miR-134 acts
as a novel EMT suppressor in NSCLC cells.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lung cancer is a highly malignant carcinoma, and most deaths
of lung cancer are caused by metastasis [1]. Recent researches have
demonstrated that epithelial-to-mesenchymal transition (EMT) is
a key process contributing to cancer metastasis, characterized by
the loss of the epithelial marker E-cadherin, an increase in the mes-
enchymal markers vimentin and N-cadherin, and an increase in the
migratory and invasive behavior [2]. Growth factors, including
especially transforming growth factor-b1 (TGF-b1), orchestrate
the EMT of various epithelial tissues [3–5]. It is identiﬁed as a main
inducer of EMT in lung adenocarcinoma and pancreatic cancer
[6,7].
MiRNAs are small, non-coding RNAs that modulate gene
expression post-transcriptionally. Aberrant expression of miRNAs
occurs in many types of cancers, some of which function as tumor
suppressor genes or oncogenes [8,9]. Some studies have implied
that miRNAs act as crucial modulators for EMT [10–12]. Recently,
it was found that the steady state level of miR-134 is modulated
by members of the p53/p73/p63 family as part of a miRNA-tumor
suppressor network [13]. However, for miR-134, the possible roleschemical Societies. Published by E
ry Diseases, Yinzhou People’s
ina. Fax: +86 574 87016828.
).and related target genes in non-small cell lung cancer (NSCLC) are
still not well elucidated.
In this study, we found that miR-134 expression correlated with
invasive potential and EMT phenotype of NSCLC cells. Functional
assays demonstrated that miR-134 inhibited EMT in NSCLC cells.
Moreover, FOXM1, a potential metastasis promoter, was identiﬁed
as a direct and functional target of miR-134.
2. Materials and methods
2.1. Cell lines and cell transfection
Four human NSCLC cell lines, including H1395, A549, Calu1 and
H1299, were grown in Dulbecco’s modiﬁed Eagle medium (DMEM)
(GIBCO BRL, Grand Island, NY) containing 10% fetal bovine serum
(FBS) with 100 lg/ml penicillin/streptomycin at 37 C with 5%
CO2. For the induction of EMT, cells were treated with 5 ng/ml
TGFb (transforming growth factor b) 1 as described previously [6].
miR-134 mimics and negative control mimics (NC), miR-134
inhibitors (anti-miR-134) and negative control inhibitors (anti-
NC) and FOXM1 siRNAs were synthesized by GenePharma
Company (Shanghai, China). Transfection was performed with
Lipofectamine 2000 (Invitrogen, CA, USA) according to the
manufacturer’s protocol. Total RNA and protein were prepared
48 h after transfection and were used for qRT-PCR or Western blot
analysis.lsevier B.V. All rights reserved.
Fig. 1. Association between miR-134 expression and invasive potential and EMT
features of NSCLC cell lines. (A) miR-134 levels in the panel of NSCLC cell lines were
determined by qRT-PCR. (B) Invasive ability of NSCLC cells was evaluated by
invasion assays. (C) Western blot analysis of epithelial marker E-cadherin and
mesenchymal marker vimentin in the panel of NSCLC cell lines.
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Wild-type 30 untranslated region (30UTR) of FOXM1 containing
predicted miR-134 target sites were ampliﬁed by PCR from
H1299 cell genomic DNA. Primers used: Forward: GAT CTG CAG
TTG CCC CTG TGC TCA AGC TG; Reverse: GAT CAT ATG AGA AAC
ATC TAA TAG CGC AC. Mutant 30UTRs were generated by over-
lap-extension PCR method. Both wild-type and mutant 30UTR frag-
ments were subcloned into the pGL3-control vector (Promega,
Madison, WI) immediately downstream of the stop codon of the
luciferase gene, as described before [14]. DNA fragment coding
FOXM1 protein was ampliﬁed by PCR from H1299 cell cDNA, and
cloned into pCMV-Myc expression vector (Clonetech, Mountain
View, CA). Primers used: Forward: GCT GAA TTC GGA TGA AAA
CTA GCC CCC GTC GGC; Reverse: CTG CTC GAG CTA CTG TAG
CTC AGG AAT AAA C.
2.3. RNA extraction and qRT-PCR
Total RNA was extracted from the cultured cells using Trizol
Reagent (Invitrogen, CA, USA) according to the manufacturer’s
protocol. qRT-PCR was used to conﬁrm the expression levels of
miRNAs as described before [15]. U6 snRNA levels were used for
normalization.
2.4. Western blot analysis
Protein extracts were prepared by a modiﬁed RIPA buffer with
0.5% sodium dodecyl sulfate (SDS) in the presence of proteinase
inhibitor cocktail (Complete mini, Roche, Indianapolis, IN, USA).
Polyacrylamide gel electrophoresis, tank-based transfer to
Immobilon Hybond-C membranes (Amersham Biosciences) and
immunodetection were performed with standard techniques.
Antibodies against FOXM1 (Novus Biologicals, CO., USA), b-actin
(Beijing Zhongshan Biotechnology, Beijing, China), E-cadherin and
vimentin (Santa Cruz, CA) were used in western analysis in accor-
dance with the manufacturer’s instruction. Signals were visualized
with SuperSignal West Pico chemoluminescent substrate (Pierce,
Rockford, III, USA) by exposure to ﬁlms.
2.5. Luciferase assay
H1299 cells were transfected in 24-well plates using Lipofect-
amine 2000 (Invitrogen, Carlsbad, CA). The transfection mixtures
contained 100 ng of ﬁreﬂy luciferase reporter plasmid and 5 pmol
of miR-134. pRL-TK (Promega, Madison, WI) was also transfected
as a normalisation control. Cells were collected 48 h after transfec-
tion, and luciferase activity was measured using a dual-luciferase
reporter assay system (Promega, Madison, WI).
2.6. Cell invasion assay
For the invasion assays, 2  105 cells were added into the upper
chamber of the insert precoated with Matrigel (ECM gel, Sigma–Al-
drich, St. Louis, MO). Cells were plated in medium without serum,
and medium containing 10% fetal bovine serum in the lower cham-
ber served as chemoattractant. After several hours of incubation,
the cells that did not invade through the pores were carefully
wiped out with cotton wool. Then the inserts were ﬁxed with
95% ethanol, stained with 0.2% crystal violet, and counted (ﬁve
high-power ﬁelds/chamber) using an inverted microscope.
2.7. Statistical analysis
All data from three independent experiments were expressed as
mean ± S.D. Differences were assessed by two-tailed Student’s ttest using Excel software. P < 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. miR-134 expression correlates with invasive potential and EMT
phenotype of NSCLC cells
We have screened four different NSCLC cell lines (A549, H1395,
Calu1 and H1299), for their invasive capabilities and expression of
miR-134. We found that miR-134 expression was inversely corre-
lated with invasive capabilities (Fig. 1A and B). Consistent with
this, low invasive cells expressed higher endogenous E-cadherin
while relatively higher levels of vimentin expression were ob-
served in highly invasive cell lines (Fig. 1B and C). These results
suggest that downregulation of miR-134 may contribute to EMT-
derived invasive phenotype in NSCLC cells.
3.2. miR-134 regulates EMT in NSCLC cells
Since A549 cells showed signiﬁcantly higher miR-134 expres-
sion (Fig. 1A) compared to H1299 cells, we selected these two cell
lines to verify our hypothesis. As shown in Fig. 2A, ectopic transfec-
tion of miR-134 mimics led to a dramatic decrease in vimentin
expression and a signiﬁcant increase in E-cadherin expression in
H1299 cells. When the A549 cells were treated with anti-miR-
134, a decrease in E-cadherin expression and an increase in
Fig. 2. miR-134 regulates EMT in NSCLC cells. (A) Ectopic expression of miR-134
notably inhibited cell EMT of H1299 cells. Inversely, miR-134 inhibitor stimulated
cell EMT of A549 cells. (B) miR-134 inhibit invasion of H1299 cells, while inhibition
of miR-134 enhances invasion in A549 cells (⁄P < 0.05).
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found that the increased miR-134 level in H1299 resulted in re-
duced cell invasion and the reduced miR-134 level in A549 led to
enhanced cell invasion (Fig 2B).
3.3. miR-134 directly targets FOXM1
Using online miRNA target prediction databases (miRNA.org
and Targetscan), we hypothesized that FOXM1 was a target of
miR-134 (Fig. 3A). As shown in Fig. 1A and Fig. 3B, A549 cells
showed signiﬁcantly higher miR-143 expression and lower FOXM1
protein expression compared to H1299 cells. Western blot showed
that the enhanced miR-134 in H1299 cells signiﬁcantly repressed
FOXM1 protein expression compared to cells transfected with
negative control (Fig. 3C). Relatively, downregulation of miR-134
by inhibitors in A549 cells led to a moderate increase of FOXM1
protein level (Fig. 3C). To further investigate if the predictedFig. 3. miR-134 directly targets FOXM1 by binding to its 30UTR. (A) The predicted miR-13
as shown. (B) Variable FOXM1 expression in four NSCLC cell lines was obtained by Weste
expression, while reduction of miR-134 by inhibitors moderately restored FOXM1 expres
FOXM1 by binding with its 30UTR.binding site of miR-134 to 30UTR of FOXM1 is responsible for this
regulation, we cloned the 30UTR of FOXM1 downstream to a
luciferase reporter gene (wt-FOXM1), its mutant version (mut-
FOXM1) by the binding site mutagenesis was also constructed.
We co-transfected wt-FOXM1 vector and miR-134 mimics or
negative control into A549 cells. The luciferase activity of
miR-134 transfected cells was signiﬁcantly reduced compared to
negative control cells (Fig. 3D). Moreover, miR-134-mediated
repression of luciferase activity was abolished by the mutant puta-
tive binding site (Fig. 3D). These results indicate that miR-134
downregulates FOXM1 expression by directly targeting its 30UTR.
3.4. FOXM1 is involved in TGF-b1-induced EMT in A549 cells
To fully explore the roles of FOXM1 in EMT, we treated A549
cells with TGF-b1. As illustrated in Fig. 4A, si-FOXM1 reversed
the expression of E-cadherin and vimentin induced by TGF-b1
treatment, and seemed to change the morphology from mesenchy-
mal-like spindle-cell shape to epithelial-like appearance in A549
cells, which resembled the inhibitory effects of miR-134. Moreover,
TGF-b1 treatment also led to a dramatic increase in FOXM1 expres-
sion and a signiﬁcant decrease in miR-134 expression (Fig. 4B and
C). In addition, utilizing pCMV-Myc expression vector, FOXM1 con-
struct without wild 30UTR was generated to carry out rescue exper-
iments. As shown in Fig. 4D, the inhibition effect of miR-134 on
EMT was rescued when FOXM1 expression vector was cotrans-
fected. These results indicated that miR-134 inhibits EMT through
regulating FOXM1 expression in NSCLC cells.
4. Discussion
The current work shows that miR-134 expression correlates
with invasive potential and EMT phenotype of NSCLC cells. It is also
shown that FOXM1 is suppressed by miR-134 via direct binding to
the FOXM1 30UTR. Moreover, we show that FOXM1 is involved in
TGF-b1-induced EMT in A549 cells. The date from this study sug-
gest that miR-134 acts as a novel EMT suppressor in NSCLC cells.
EMT is the key process driving cancer metastasis [2,16]. Loss of
E-cadherin expression and gain of vimentin expression are consid-
ered to be the most important molecular markers of EMT [17,18].
Recent studies have implied that miRNAs act as crucial modulators4 binding site within FOXM1 30UTR and its mutated version by site mutagenesis are
rn blot. (C) In comparison with negative controls, miR-134 inhibited FOXM1 protein
sion. (D) Luciferase assays indicated that miR-134 downregulated the expression of
Fig. 4. FOXM1 is involved in TGF-b1-induced EMT in A549 cells. A549 cells were transfected with NC, si-FOXM1 or miR-134 respectively, after 24 h, TGF-b1 (5 ng/ml) was
added, and cells were further incubated for 48 h. (A) Western blot analysis of epithelial marker E-cadherin and mesenchymal marker vimentin. At the same time, A549 cells
morphological changes were examined. The effect of TGF-b1 on FOXM1 (B) and miR-134 expression (C) were examined. (D) The inhibition effect of miR-134 on EMT was
rescued when FOXM1 expression vector was cotransfected.
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shown to inhibit EMT by targeting ZEB1 and SIP1 [10], Moreover,
miR-194 inhibits EMT of endometrial cancer cells and miR-30a
inhibits EMT in NSCLC [11,12]. Our results show that miR-134 re-
verses EMT in NSCLC cells. In addition, FOXM1 is involved in TGF-
b1-induced EMT in A549 cells.
FOXM1 belongs to a large family of forkhead box (Fox) tran-
scription factors. Overexpression of FOXM1 has been found in a
variety of aggressive human carcinomas including lung cancer
[19–23]. Interestingly, several studies on FOXM1 implicated its
involvement in the early steps of metastasis. For example, FOXM1
was shown to stimulate invasion and angiogenesis of pancreatic
cancer cells through induction of matrix metalloproteinase genes
MMP-2 and MMP-9, as well as vascular endothelial growth factor
(VEGF) [24,25]. Moreover, overexpression of FOXM1 coincides
with metastasis of prostate cancer [26]. Our results showed that
knockdown of FOXM1 by siRNA or miR-134 reversed EMT in
NSCLC cells. These ﬁndings imply that dysregulation of FOXM1
by miRNAs may be an important mechanism underlying cancer
metastasis.
miR-134 gene is located at 14q32, and is involved in several
physiological and pathological processes. For example, miR-134
plays an important role in translation-dependent guidance of nerve
growth cones [27]; miR-134 is regarded as a potential plasma bio-
marker for the diagnosis of acute pulmonary embolism [28]. Inter-
estingly, recent studies indicated that miR-134 may also be
involved in carcinogenesis. p53/p63/p73, the tumor suppressors,
were believed to be regulators of the miR-134 processing complex
[13]. Moreover, Increased expression of miR-134 contribute to the
activity of testosterone and 1,25(OH)2D3 to suppress tumor growth
in prostate cancer [29]. Our results suggest that miR-134 functions
as a potent tumor suppressor in NSCLC.
In conclusion, we newly described miR-134/FOXM1 link and
provided a potential mechanism for FOXM1 dysregulation and
contribution to NSCLC cell EMT. As a result, restoration of miR-
134 expression could have an important implication for the clinical
management of NSCLC.Acknowledgements
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